CSF biomarkers for Alzheimer’s disease: use in early diagnosis and evaluation of drug treatment

References

• Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch. Neurol. 56, 303–308 (1999).
   PubMed Web of Science ®Google Scholar
• DeCarli C. Mild cognitive impairment: prevalence, prognosis, aetiology, and treatment. Lancet Neurol. 2, 15–21 (2003).
   PubMed Web of Science ®Google Scholar
• Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, Beyreuther K. Amyloid plaque core protein in Alzheimer’s disease and Down’s syndrome. Proc. Natl Acad. Sci. USA 82, 4245–4249 (1985).
   PubMed Web of Science ®Google Scholar
• Kang J, Lemaire HG, Unterbeck A et al. The precursor of Alzheimer’s disease amyloid A4 protein resembles a cell-surface receptor. Nature 325, 733–736 (1987).
   PubMed Web of Science ®Google Scholar
• Vassar R, Bennett BD, Babu-Khan S et al. β-secretase cleavage of Alzheimer’s amyloid precursor protein by the transmembrane aspartic protease BACE. Science 286, 735–741 (1999).
   PubMed Web of Science ®Google Scholar
• Wolfe MS, Xia W, Ostaszewski BL, Diehl TS, Kimberly WT, Selkoe DJ. Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and γ-secretase activity. Nature 398, 513–517 (1999).
   PubMed Web of Science ®Google Scholar
• Li YM, Xu M, Lai MT et al. Photoactivated γ-secretase inhibitors directed to the active site covalently label presenilin 1. Nature 405, 689–694 (2000).
   PubMed Web of Science ®Google Scholar
• Yu G, Nishimura M, Arawaka S et al. Nicastrin modulates presenilin-mediated notch/glp-1 signal transduction and βAPP processing. Nature 407(6800), 48–54 (2000).
   PubMed Web of Science ®Google Scholar
• Francis R, McGrath G, Zhang J et al. Aph-1 and pen-2 are required for Notch pathway signaling, γ-secretase cleavage of βAPP, and presenilin protein accumulation. Dev. Cell 3, 85–97 (2002).
   PubMed Web of Science ®Google Scholar
• Goutte C, Tsunozaki M, Hale VA, Priess JR. APH-1 is a multipass membrane protein essential for the Notch signaling pathway in Caenorhabditis elegans embryos. Proc. Natl Acad. Sci. USA 99, 775–779 (2002).
   PubMed Web of Science ®Google Scholar
• Grundke-Iqbal I, Iqbal K, Tung YC, Quinlan M, Wisniewski HM, Binder LI. Abnormal phosphorylation of the microtubule-associated protein (tau) in Alzheimer cytoskeletal pathology. Proc. Natl Acad. Sci. USA83, 4913–4917 (1986).
   PubMed Web of Science ®Google Scholar
• Goedert M, Spillantini MG, Potier MC, Ulrich J, Crowther RA. Cloning and sequencing of the cDNA encoding an isoform of microtubule-associated protein tau containing four tandem repeats: differential expression of tau protein mRNAs in human brain. EMBO J. 8, 393–399 (1989).
   PubMed Web of Science ®Google Scholar
• Buée L, Bussiere T, Buee-Scherrer V, Delacourte A, Hof PR. Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res. Brain Res. Rev. 33, 95–130 (2000).
   PubMed Web of Science ®Google Scholar
• Iqbal K, Alonso AD, Gondal JA et al. Mechanism of neurofibrillary degeneration and pharmacologic therapeutic approach. J. Neural. Transm. Suppl. 59, 213–222 (2000).
   PubMedGoogle Scholar
• Wilkinson DG, Francis PT, Schwam E, Payne-Parrish J. Cholinesterase inhibitors used in the treatment of Alzheimer’s disease: the relationship between pharmacological effects and clinical efficacy. Drugs Aging 21, 453–478 (2004).
   PubMed Web of Science ®Google Scholar
• Tourtellotte WW, Haerer AF, Heller GL, Soners JE. Post-lumbar puncture headaches. Charles C Thomas, IL, USA (1964).
   Google Scholar
• Vandam LD, Dripps RD. Long-term follow-up of patients who received 10,098 spinal anesthetics. JAMA 161, 586–591 (1956).
   PubMed Web of Science ®Google Scholar
• Andreasen N, Minthon L, Davidsson P et al. Evaluation of CSF-tau and CSF-Aβ42 as diagnostic markers for Alzheimer’s disease in clinical practice. Arch. Neurol. 58, 373–379 (2001).
   PubMed Web of Science ®Google Scholar
• Blennow K, Wallin A, Häger O. Low frequency of post-lumbar puncture headache in demented patients. Acta Neurol. Scand. 88, 221–223 (1993).
   PubMed Web of Science ®Google Scholar
• Hampel H, Buerger K, Kohnken R et al. Tracking of Alzheimer’s disease progression with cerebrospinal fluid tau protein phosphorylated at threonine 231. Ann. Neurol. 49, 545–546 (2001).
   PubMed Web of Science ®Google Scholar
• Hesse C, Rosengren L, Vanmechelen E et al. Cerebrospinal fluid markers for Alzheimer’s disease evaluated after acute ischemic stroke. J. Alzheimers Dis. 2, 199–206 (2000).
   PubMedGoogle Scholar
• Otto M, Wiltfang J, Tumani H et al. Elevated levels of tau-protein in cerebrospinal fluid of patients with Creutzfeldt–Jakob disease. Neurosci. Lett. 225, 210–212 (1997).
   PubMed Web of Science ®Google Scholar
• Haass C, Schlossmacher MG, Hung AY et al. Amyloid β-peptide is produced by cultured cells during normal metabolism. Nature 359, 322–325 (1992).
   PubMed Web of Science ®Google Scholar
• Van Nostrand WE, Wagner SL, Shankle WR et al. Decreased levels of soluble amyloid β-protein precursor in cerebrospinal fluid of live Alzheimer’s disease patients. Proc. Natl Acad. Sci. USA 89, 2551–2555 (1992).
   PubMed Web of Science ®Google Scholar
• Farlow M, Ghetti B, Benson MD, Farrow JS, van Nostrand WE, Wagner SL. Low cerebrospinal-fluid concentrations of soluble amyloid β-protein precursor in hereditary Alzheimer’s disease. Lancet 340, 453–454 (1992).
   PubMed Web of Science ®Google Scholar
• Tabaton M, Nunzi MG, Xue R, Usiak M, Autilio-Gambetti L, Gambetti P. Soluble amyloid β-protein is a marker of Alzheimer amyloid in brain but not in cerebrospinal fluid. Biochem. Biophys. Res. Commun. 200, 1598–1603 (1994).
   PubMed Web of Science ®Google Scholar
• Motter, R, Vigo-Pelfrey, C, Kholodenko D et al. Reduction of β-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer’s disease. Ann. Neurol. 38, 643–648 (1995).
   PubMed Web of Science ®Google Scholar
• Jarrett JT, Berger EP, Lansbury PT. The carboxy terminus of the β amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer’s disease. Biochemistry 32, 4693–4697 (1993).
   PubMed Web of Science ®Google Scholar
• Iwatsubo T, Odaka A, Suzuki N, Mizusawa H, Nukina N, Ihara Y. Visualization of Aβ42(43) and Aβ40 in senile plaques with end-specific Aβ monocloncals: evidence that an initially deposited species is Aβ42(43). Neurone 13, 45–53 (1994).
   PubMed Web of Science ®Google Scholar
• Vanderstichele H, Blennow K, D’Heuvaert ND et al. Development of a specific diagnostic test for measurement of β-amyloid1–42 in CSF. In: Progress in Alzheimer’s and Parkinson’s diseases. Fisher A, Hanin I, Yoshida M (Eds), Plenum Press, NY, USA, 773–778 (1998).
   Google Scholar
• Blennow K, Vanmechelen E, Hampel H. CSF total tau, Aβ42 and phosphorylated tau protein as biomarkers for Alzheimer’s disease. Mol. Neurobiol. 24, 87–97 (2001).
   PubMed Web of Science ®Google Scholar
• Sjögren M, Davidsson P, Wallin A et al. Decreased CSF β-amyloid42 in Alzheimer’s disease and amyotrophic lateral sclerosis may reflect mismetabolism of β-amyloid induced by separate mechanisms. Dementia Geriatr. Cogn. Disord. 13, 112–118 (2002).
   PubMed Web of Science ®Google Scholar
• Holmberg B, Johnels B, Blennow K, Rosengren L. Cerebrospinal fluid Aβ42 is reduced in multiple system atrophy but normal in Parkinson’s disease and progressive supranuclear palsy. Mov. Disord. 18, 186–190 (2003).
   PubMed Web of Science ®Google Scholar
• Kanai M, Matsubara E, Isoe K et al. Longitudinal study of cerebrospinal fluid levels of tau, Aβ1–40, and Aβ1–42(43) in Alzheimer’s disease: a study in Japan. Ann. Neurol. 44, 17–26 (1998).
   PubMed Web of Science ®Google Scholar
• Shoji M, Matsubara E, Kanai M et al. Combination assay of CSF tau, Aβ1–40 and Aβ1–42(43) as a biochemical marker of Alzheimer’s disease. J. Neurol. Sci. 158, 134–140 (1998).
   PubMed Web of Science ®Google Scholar
• Fukuyama R, Mizuno T, Mori S, Nakajima K, Fushiki S, Yanagisawa K. Age-dependent change in the levels of Aβ40 and Aβ42 in cerebrospinal fluid from control subjects, and a decrease in the ratio of Aβ42 to Aβ40 level in cerebrospinal fluid from Alzheimer’s disease patients. Eur. Neurol. 43, 155–160 (2000).
   PubMed Web of Science ®Google Scholar
• Lewczuk P, Esselmann H, Otto M et al. Neurochemical diagnosis of Alzheimer’s dementia by CSF Aβ42, Aβ42/Aβ40 ratio and total tau. Neurobiol. Aging 25, 273–281 (2004).
   PubMed Web of Science ®Google Scholar
• Wiltfang J, Esselmann H, Bibl M et al. Highly conserved and disease-specific patterns of carboxyterminally truncated Aβ peptides 1–37/38/39 in addition to 1–40/42 in Alzheimer’s disease and in patients with chronic neuroinflammation. J. Neurochem. 81, 481–496 (2002).
   PubMed Web of Science ®Google Scholar
• Höglund K, Syversen S, Lewczuk P, Wallin A, Wiltfang J, Blennow K. The effect of statin treatment on a highly conserved and disease-specific peptide pattern of Aβ peptides in patients with Alzheimer’s disease. Exp. Brain Res. 164(2), 205–214 (2005).
   PubMed Web of Science ®Google Scholar
• Lewczuk P, Esselmann H, Meyer M et al. The amyloid-β (Aβ) peptide pattern in cerebrospinal fluid in Alzheimer’s disease: evidence of a novel carboxyterminally elongated Aβ peptide. Rapid Commun. Mass Spectrom. 17, 1291–1296 (2003).
   PubMed Web of Science ®Google Scholar
• Klein WL. Aβ toxicity in Alzheimer’s disease: globular oligomers (ADDLs) as new vaccine and drug targets. Neurochem. Int. 41, 345–352 (2002).
   PubMed Web of Science ®Google Scholar
• Georganopoulou DG, Chang L, Nam JM et al. Nanoparticle-based detection in cerebral spinal fluid of a soluble pathogenic biomarker for Alzheimer’s disease. Proc. Natl Acad. Sci. USA 102, 2273–2276 (2005).
   PubMed Web of Science ®Google Scholar
• Blennow K, Nellgård B. Amyloid β1–42 and tau in CSF after severe traumatic brain injury. Neurology 62, 159–160 (2003).
   Google Scholar
• Vandermeeren M, Mercken M, Vanmechelen E et al. Detection of τ proteins in normal and Alzheimer’s disease cerebrospinal fluid with a sensitive sandwich enzyme-linked immunosorbent assay. J. Neurochem. 61, 1828–1834 (1993).
   PubMed Web of Science ®Google Scholar
• Blennow K, Wallin A, Ågren H, Spenger C, Siegfried J, Vanmechelen E. Tau protein in cerebrospinal fluid: a biochemical diagnostic marker for axonal degeneration in Alzheimer’s disease? Mol. Chem. Neuropathol. 26, 231–245 (1995).
   PubMedGoogle Scholar
• Vigo-Pelfrey C, Seubert P, Barbour R et al. Elevation of microtubule-associated protein tau in the cerebrospinal fluid of patients with Alzheimer’s disease. Neurology 45, 788–793 (1995).
   PubMed Web of Science ®Google Scholar
• Vanmechelen E, Vanderstichele H, Davidsson P et al. Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization. Neurosci. Lett. 285, 49–52 (2000).
   PubMed Web of Science ®Google Scholar
• Ishiguro K, Ohno H, Arai H et al. Phosphorylated tau in human cerebrospinal fluid is a diagnostic marker for Alzheimer’s disease. Neurosci. Lett. 270, 91–94 (1999).
   PubMed Web of Science ®Google Scholar
• Kohnken R, Buerger K, Zinkowski R et al. Detection of tau phosphorylated at threonine 231 in cerebrospinal fluid of Alzheimer’s disease patients. Neurosci. Lett. 287, 187–190 (2000).
   PubMed Web of Science ®Google Scholar
• Hu YY, He SS, Wang X et al. Levels of nonphosphorylated and phosphorylated tau in cerebrospinal fluid of Alzheimer’s disease patients: an ultrasensitive bienzyme-substrate-recycle enzyme-linked immunosorbent assay. Am. J. Pathol. 160, 1269–1278 (2002).
   PubMed Web of Science ®Google Scholar
• Hampel H, Buerger K, Zinkowski R et al. Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer’s disease: a comparative cerebrospinal fluid study. Arch. Gen. Psychiatr. 61, 95–102 (2004).
   PubMed Web of Science ®Google Scholar
• Hesse C, Rosengren L, Andreasen N et al. Transient increase in CSF total tau but not phospho-tau after acute stroke. Neurosci. Lett. 297, 187–190 (2001).
   PubMed Web of Science ®Google Scholar
• Riemenschneider M, Wagenpfeil S, Vanderstichele H et al. Phospho-tau/total tau ratio in cerebrospinal fluid discriminates Creutzfeldt–Jakob disease from other dementias. Mol. Psychiatr. 8, 343–347 (2003).
   PubMed Web of Science ®Google Scholar
• Blennow K, Hampel H. CSF markers for incipient Alzheimer’s disease. Lancet Neurol. 2, 605–613 (2003).
   PubMed Web of Science ®Google Scholar
• Maddalena A, Papassotiropoulos A, Muller-Tillmanns B et al. Biochemical diagnosis of Alzheimer’s disease by measuring the cerebrospinal fluid ratio of phosphorylated tau protein to β-amyloid peptide42. Arch. Neurol. 60, 1202–1206 (2003).
   PubMedGoogle Scholar
• Riemenschneider M, Lautenschlager N, Wagenpfeil S, Diehl J, Drzezga A, Kurz A. Cerebrospinal fluid tau and β-amyloid 42 proteins identify Alzheimer’s disease in subjects with mild cognitive impairment. Arch. Neurol. 59, 1729–1734 (2002).
   PubMed Web of Science ®Google Scholar
• Sjögren M, Minthon L, Davidsson P et al. CSF levels of tau, β-amyloid1–42 and GAP-43 in frontotemporal dementia, other types of dementia and normal aging. J. Neural. Transm. 107, 563–579 (2000).
   PubMed Web of Science ®Google Scholar
• Kapaki E, Paraskevas GP, Zalonis I, Zournas C. CSF tau protein and β-amyloid1–42 in Alzheimer’s disease diagnosis: discrimination from normal ageing and other dementias in the Greek population. Eur. J. Neurol. 10, 119–128 (2003).
   PubMed Web of Science ®Google Scholar
• Andreasen N, Hesse C, Davidsson P et al. Cerebrospinal fluid β-amyloid1–42 in Alzheimer’s disease: differences between early- and late-onset Alzheimer’s disease and stability during the course of disease. Arch. Neurol. 56, 673–680 (1999).
   PubMed Web of Science ®Google Scholar
• Andreasen N, Vanmechelen E, Van de Voorde A et al. Cerebrospinal fluid tau protein as a biochemical marker for Alzheimer’s disease: a community-based follow-up study. J. Neurol. Neurosurg. Psychiatr. 64, 298–305 (1998).
   PubMed Web of Science ®Google Scholar
• Sjögren M, Davidsson P, Tullberg M et al. Both total and hyperphosphorylated tau are increased in Alzheimer’s disease. J. Neurol. Neurosurg. Psychiatr. 70, 624–630 (2001).
   PubMed Web of Science ®Google Scholar
• Sjögren M, Davidsson P, Gottfries J et al. The cerebrospinal fluid levels of tau, growth-associated protein-43 and soluble amyloid precursor protein correlate in Alzheimer’s disease, reflecting a common pathophysiological process. Dement. Geriatr. Cogn. Disord. 12, 257–264 (2001).
   PubMed Web of Science ®Google Scholar
• Gomez-Tortosa E, Gonzalo I, Fanjul S et al. Cerebrospinal fluid markers in dementia with lewy bodies compared with Alzheimer’s disease. Arch. Neurol. 60, 1218–1222 (2003).
   PubMedGoogle Scholar
• Wallin A, Sjögren M, Davidsson P, Blennow K. Decreased cerebrospinal fluid acetylcholinesterase in patients with subcortical ischemic vascular dementia. Dement. Geriatr. Cogn. Disord. 16, 200–207 (2003).
   PubMed Web of Science ®Google Scholar
• Andreasen N, Minthon L, Clarberg A et al. Sensitivity, specificity and stability of CSF t-tau in AD in a community-based patient sample. Neurology 53, 1488–1494 (1999).
   PubMed Web of Science ®Google Scholar
• Parnetti L, Lanari A, Amici S, Gallai V, Vanmechelen E, Hulstaert F. CSF phosphorylated tau is a possible marker for discriminating Alzheimer’s disease from dementia with Lewy bodies. Phospho-Tau International Study Group. Neurol. Sci. 22, 77–78 (2001).
   PubMed Web of Science ®Google Scholar
• Buerger K, Zinkowski R, Teipel SJ et al. Differential diagnosis of Alzheimer’s disease with cerebrospinal fluid levels of tau protein phosphorylated at threonine 231. Arch. Neurol. 59, 1267–1272 (2002).
   PubMed Web of Science ®Google Scholar
• Kanemaru K, Kameda N, Yamanouchi H. Decreased CSF amyloid β42 and normal tau levels in dementia with Lewy bodies. Neurology 54, 1875–1876 (2000).
   PubMed Web of Science ®Google Scholar
• Olsson A, Vanderstichele H, Andreasen N et al. Simultaneous measurement of β-amyloid1–42, total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology. Clin. Chem. 51, 336–345 (2005).
   PubMed Web of Science ®Google Scholar
• Zetterberg H, Blennow K. Elevated total tau/phospho-tau ratio in autopsy-proven Creutzfeldt–Jakob disease with negative 14-3-3 test results. Neurol. Sci. 25, 301–302 (2004).
   PubMed Web of Science ®Google Scholar
• Hulstaert F, Blennow K, Ivanoiu A et al. Improved discrimination of AD patients using β-amyloid1–42 and tau levels in CSF. Neurology 52, 1555–1562 (1999).
   PubMed Web of Science ®Google Scholar
• Galasko D, Chang L, Motter R et al. High cerebrospinal fluid tau and low amyloid β42 levels in the clinical diagnosis of Alzheimer’s disease and relation to apolipoprotein E genotype. Arch. Neurol. 55, 937–945 (1998).
   PubMedGoogle Scholar
• Sunderland T, Linker G, Mirza N et al. Decreased β-amyloid1–42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer’s disease. JAMA 289, 2094–2103 (2003).
   PubMed Web of Science ®Google Scholar
• Arai H, Nakagawa T, Kosaka Y et al. Elevated cerebrospinal fluid tau protein level as a predictor of dementia in memory-impaired patients. Alzheimer’s Res. 3, 211–213 (1997).
   Google Scholar
• Buerger K, Teipel SJ, Zinkowski R et al. CSF tau protein phosphorylated at threonine 231 correlates with cognitive decline in MCI subjects. Neurology 59, 627–629 (2002).
   PubMed Web of Science ®Google Scholar
• Ivanoiu A, Sindic CJ. Cerebrospinal fluid Tau protein and amyloid β42 in mild cognitive impairment: prediction of progression to Alzheimer’s disease and correlation with the neuropsychological examination. Neurocase 11, 32–39 (2005).
   PubMed Web of Science ®Google Scholar
• Andreasen N, Minthon L, Vanmechelen E et al. CSF-tau and CSF-Aβ42 as predictors of development of Alzheimer’s disease in patients with mild cognitive impairment. Neurosci. Lett. 273, 5–8 (1999).
   PubMed Web of Science ®Google Scholar
• Zetterberg H, Wahlund LO, Blennow K. Cerebrospinal fluid markers for prediction of Alzheimer’s disease. Neurosci. Lett. 352, 67–69 (2003).
   PubMed Web of Science ®Google Scholar
• Sjögren M, Vanderstichele H, Ågren H et al. Tau and Aβ42 in cerebrospinal fluid from healthy adults 21–93 years of age: establishment of reference values. Clin. Chem. 47, 1776–1781 (2001).
   PubMed Web of Science ®Google Scholar
• Schoonenboom NS, Mulder C, Vanderstichele H et al. Effects of processing and storage conditions on amyloid β1–42 and tau concentrations in cerebrospinal fluid: implications for use in clinical practice. Clin. Chem. 51, 189–195 (2005).
   PubMed Web of Science ®Google Scholar
• Vanderstichele H, Van Kerschaver E, Hesse C et al. Standardization of measurement of β-amyloid1–42 in cerebrospinal fluid and plasma. Amyloid 7, 245–258 (2000).
   PubMed Web of Science ®Google Scholar
• Davidsson P, Blennow K, Andreasen N, Eriksson B, Minthon L, Hesse C. Differential increase in cerebrospinal fluid-acetylcholinesterase after treatment with acetylcholinesterase inhibitors in patients with Alzheimer’s disease. Neurosci. Lett. 300, 157–160 (2001).
   PubMed Web of Science ®Google Scholar
• Parnetti L, Amici S, Lanari A et al. Cerebrospinal fluid levels of biomarkers and activity of acetylcholinesterase (AChE) and butyrylcholinesterase in AD patients before and after treatment with different AChE inhibitors. Neurol. Sci. 23(Suppl. 2), S95–S96 (2002).
   PubMed Web of Science ®Google Scholar
• Amici S, Lanari A, Romani R, Antognelli C, Gallai V, Parnetti L. Cerebrospinal fluid acetylcholinesterase activity after long-term treatment with donepezil and rivastigmine. Mech. Ageing Dev. 122, 2057–2062 (2001).
   PubMed Web of Science ®Google Scholar
• Maelicke A, Albuquerque EX. Allosteric modulation of nicotinic acetylcholine receptors as a treatment strategy for Alzheimer’s disease. Eur. J. Pharmacol. 393, 165–170 (2000).
   PubMed Web of Science ®Google Scholar
• Giacobini E. Invited review: cholinesterase inhibitors for Alzheimer’s disease therapy: from tacrine to future applications. Neurochem. Int. 32, 413–419 (1998).
   PubMed Web of Science ®Google Scholar
• Anderson JJ, Holtz G, Baskin PP et al. Reductions in β-amyloid concentrations in vivo by the γ-secretase inhibitors BMS-289948 and BMS-299897. Biochem. Pharmacol. 69, 689–698 (2005).
   PubMed Web of Science ®Google Scholar
• Gilman S, Koller M, Black RS et al. Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial. Neurology 64, 1153–1562 (2005).
   Google Scholar
• Zhukareva V, Trojanowski JQ, Lee VM. Assessment of pathological tau proteins in frontotemporal dementias: qualitative and quantitative approaches. Am. J. Geriatr. Psychiatr. 12, 136–145 (2004).
   PubMed Web of Science ®Google Scholar
• Price JL, Morris JC. Tangles and plaques in nondemented aging and ‘preclinical’ Alzheimer’s disease. Ann. Neurol. 45, 358–368 (1999).
   PubMed Web of Science ®Google Scholar
• Mikolaenko I, Pletnikova O, Kawas CH et al. α-synuclein lesions in normal aging, Parkinson’s disease, and Alzheimer’s disease: evidence from the Baltimore Longitudinal Study of Aging (BLSA). J. Neuropathol. Exp. Neurol. 64, 156–162 (2005).
   PubMed Web of Science ®Google Scholar
• Kotzbauer PT, Trojanowsk JQ, Lee VM. Lewy body pathology in Alzheimer’s disease. J. Mol. Neurosci. 17, 225–232 (2001).
   PubMed Web of Science ®Google Scholar
• Jellinger KA. Diagnostic accuracy of Alzheimer’s disease: a clinicopathological study. Acta Neuropathol. 91, 219–220 (1996).
   PubMed Web of Science ®Google Scholar
• Kosunen O, Soininen H, Paljärvi L et al. Diagnostic accuracy of Alzheimer’s disease: a neuropathological study. Acta Neuropathol. 91, 185–193 (1996).
   PubMed Web of Science ®Google Scholar
• Best JD, Jay MT, Otu F et al. Quantitative measurement of changes in amyloid-β40 in the rat brain and cerebrospinal fluid following treatment with the γ-secretase inhibitor LY-411575 [N2-[(2S)-2-(3,5-Difluorophenyl)-2-hydroxyethanoyl]-N1-[(7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl]-l-alaninamide]. J. Pharmacol. Exp. Ther. 313, 902–908 (2005).
   PubMed Web of Science ®Google Scholar
• Tang N, Tornatore P, Weinberger SR. Current developments in SELDI affinity technology. Mass Spectrom. Rev. 23, 34–44 (2004).
   PubMed Web of Science ®Google Scholar
• Carrette O, Demalte I, Scherl A et al. A panel of cerebrospinal fluid potential biomarkers for the diagnosis of Alzheimer’s disease. Proteomics 3, 1486–1494 (2003).
   PubMed Web of Science ®Google Scholar
• Davies H, Lomas L, Austen B. Profiling of amyloid β peptide variants using SELDI Protein Chip arrays. Biotechniques 27, 1258–1261 (1999).
   PubMed Web of Science ®Google Scholar
• Hagman C, Ramstrom M, Jansson M, James P, Hakansson P, Bergquist J. Reproducibility of tryptic digestion investigated by quantitative fourier transform ion cyclotron resonance mass spectrometry. J. Proteome Res. 4, 394–399 (2005).
   PubMed Web of Science ®Google Scholar